"Glucocorticoids" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
| Descriptor ID |
D005938
|
| MeSH Number(s) |
D06.472.040.543 D27.505.696.399.472.488
|
| Concept/Terms |
Glucocorticoid Effect- Glucocorticoid Effect
- Effect, Glucocorticoid
- Glucorticoid Effects
- Effects, Glucorticoid
|
Below are MeSH descriptors whose meaning is more general than "Glucocorticoids".
Below are MeSH descriptors whose meaning is more specific than "Glucocorticoids".
This graph shows the total number of publications written about "Glucocorticoids" by people in this website by year, and whether "Glucocorticoids" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 4 | 7 |
| 2001 | 3 | 1 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 3 | 3 |
| 2008 | 2 | 2 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 3 | 4 | 7 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 3 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 8 | 3 | 11 |
| 2019 | 1 | 5 | 6 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 3 | 4 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucocorticoids" by people in Profiles.
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res (Hoboken). 2024 Aug; 76(8):1051-1069.
-
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol. 2024 Aug; 76(8):1182-1200.
-
Anti-inflammatory medication use after cataract surgery: online survey of practice patterns. J Cataract Refract Surg. 2024 Mar 01; 50(3):224-229.
-
Outcomes of giant cell arteritis patients treated with tocilizumab in a single neuro-ophthalmology practice. Can J Ophthalmol. 2023 04; 58(2):e61-e62.
-
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
-
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 07; 81(7):962-969.
-
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
-
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021 12; 8(1).
-
Glucocorticoid-mediated induction of caveolin-1 disrupts cytoskeletal organization, inhibits cell migration and re-epithelialization of non-healing wounds. Commun Biol. 2021 06 18; 4(1):757.
-
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul; 30(8):1254-1263.